vitamin-b-12 and Neoplasm-Metastasis

Topics: Anemia; Anemia, Hemolytic; Blood Circulation; Bone Marrow; Catalase; Erythrocytes; Ferritins; Hemoglobins; Hemolysis; Hemorrhage; Humans; Iron; Metals; Mononuclear Phagocyte System; Neoplasm Metastasis; Neoplasms; Polysaccharides, Bacterial; Regional Blood Flow; Vitamin B 12

Topics: Bone Neoplasms; Calcium Isotopes; Child, Preschool; Contrast Media; Humans; Intestinal Absorption; Iodine Radioisotopes; Iodipamide; Iron; Neoplasm Metastasis; Potassium Isotopes; Radiometry; Strontium Isotopes; Vitamin B 12

In some reports, 5-fluorouracil has been associated with modest activity in patients with neuroendocrine tumors. Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors.. Patients with metastatic neuroendocrine tumors (excluding small-cell carcinoma) were treated with pemetrexed administered intravenously at a dose of 500 mg/m(2) every 21 days. To reduce potential toxicity, patients also received folic acid, vitamin B12 supplementation, and peri-infusional treatment with dexamethasone. Patients were followed for response, toxicity, and survival.. The study was designed with a total accrual goal of 32 patients. Due to lack of radiographic responses in patients during the study period, accrual was terminated at 17. However, one patient achieved a delayed partial response following discontinuation of pemetrexed. Ten patients were evaluable for biochemical response; five (50%) experienced >50% decrease in plasma chromogranin A. Among the 17 patients, 5 (29%) discontinued therapy due to treatment-related toxicity. The median overall survival was 12.1 months.. Pemetrexed does not appear to have significant antitumor activity in patients with advanced neuroendocrine tumors. The limited antitumor activity and potential toxicity associated with pemetrexed mirrors experience with the majority of other cytotoxic agents in patients with neuroendocrine tumors. Investigation of novel, molecularly targeted agents may offer more promise in this disease.

Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dexamethasone; Female; Folic Acid; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pemetrexed; Survival; Treatment Outcome; Vitamin B 12; Vitamin B Complex

Gemcitabine (G) plus cisplatin (C) is standard care for metastatic transitional cell carcinoma (TCC) of the urothelium. Pemetrexed (P), alone or in combination with G, is active in metastatic TCC. However, the safety and efficacy of P combined with GC therapy is unknown. This phase I trial was designed to determine the maximum tolerated dose (MTD) of GC followed by P+G in patients with metastatic TCC.. Cohorts of 3 to 6 patients received escalating doses 28-day cycles (maximum 6 cycles): G 800-1,000 mg/m2 on days 1 and 15; P 400-500 mg/m2 on day 15; and C 50-70 mg/m2 on day 1. All patients received folic acid, vitamin B12, and full supportive care. The 3+3 standard phase I escalation rule was used to determine MTD.. Fifteen patients registered: 13/15 white males; median age 70 years (range, 53-82); 11/15 had KPS>or=90. At dose level 0, 2/4 patients experienced unrelated DLTs, and 1 patient was replaced (completed<1 cycle). Dose escalation proceeded to dose level 1. At level 1, 4/6 patients experienced DLTs; dosing decreased to level 0 and 4/5 patients experienced DLTs. The MTD was not determined. The 2 patients that completed 6 cycles both had partial responses. Grades 3-4 hematologic toxicities included neutropenia (60%), leukopenia (20%), and febrile neutropenia (13%).. Adding P to the standard GC regimen as first-line therapy for metastatic TCC produced no benefit. The MTD exceeded therapeutic gemcitabine and cisplatin doses for urothelial cancer and thus the study was aborted.

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vitamin B 12; Vitamin B Complex

Pemetrexed has demonstrated activity in hepatocellular carcinoma (HCC) cell lines, and has a manageable toxicity profile in clinical trials, suggesting its potential as a treatment for HCC patients. A multicenter, Phase II community-based study was conducted to assess the response rate and toxicity profile of single-agent pemetrexed in first-line patients with advanced or metastatic HCC. Patients premedicated with folic acid, vitamin B(12), and dexamethasone were administered pemetrexed 600 mg/m(2) IV on day 1 of each 21-day cycle until disease progression. This nonrandomized study employed Simon's 2-stage design, enrolling 21 eligible patients in the first stage, stopping accrual if < or =2 responders were observed. Responses were four stable disease, 14 progressive disease, and three not evaluable: two had early toxicities (renal/liver failure, sepsis) and one was noncompliant. The most common grade 3 hematological toxicities were neutropenia 6 of 21 (29%) and thrombocytopenia 3 of 21 (14%); with no grade 4 toxicities. Thirteen patients died on-study: 12 PD and one liver failure; none were drug-related. The median survival was 5.2 months (range, <1-12.2). The planned second stage was cancelled, and the trial was closed owing to lack of response. While pemetrexed was tolerated in this patient population, it was not active.

Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dexamethasone; Disease Progression; Female; Folic Acid; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome; Vitamin B 12

The objective of this study was to assess the efficacy and safety of pemetrexed in pretreated patients with advanced-stage breast cancer.. Patients with advanced-stage or metastatic breast cancer, Eastern Cooperative Oncology Group performance status 0-2, and progressive or relapsed disease after treatment with regimens containing anthracyclines and taxanes were eligible. Pemetrexed 500 mg/m2 was administered as a 10-minute intravenous infusion on day 1 every 21 days.. Seventy-nine women were enrolled. After protocol amendment, 43 patients received folic acid and vitamin B12 supplementation to control pemetrexed-related toxicity. A median of 4 cycles (range, 1-23 cycles) was administered. Overall response rate was 9% (95% confidence interval, 3.7%-17.6%), median duration of response was 5.5 months, median progression-free survival was 3.1 months, and median survival was 10.5 months. Major grade 3/4 toxicities were lymphopenia (53.3%), neutropenia (36.4%), leukopenia (26.9%), and anemia (7.7%). In general, the toxicities were less frequent in patients who received vitamin supplementation than in those who did not receive vitamin supplementation.. The response to pemetrexed salvage treatment was low in this study of heavily pretreated patients with breast cancer. Pemetrexed was generally well tolerated in patients with previously treated breast cancer. Vitamin supplementation appeared to ameliorate toxicity.

Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Female; Folic Acid; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Premedication; Salvage Therapy; Taxoids; Vitamin B 12; Vitamin B Complex

Targeting cancer cells with vitamin B12 (cobalamin) is hampered by unwanted physiologic tissue uptake mediated by transcobalamin. Adhering to good manufacturing practice, we have developed a new (99m)Tc-cobalamin derivative ((99m)Tc(CO)3-[(4-amido-butyl)-pyridin-2-yl-methyl-amino-acetato] cobalamin, (99m)Tc-PAMA-cobalamin). The derivative shows no binding to transcobalamin but is recognized by haptocorrin, a protein present in the circulation and notably expressed in many tumor cells. In this prospective study, we investigated cancer-specific uptake of (99m)Tc-PAMA-cobalamin in 10 patients with various metastatic tumors.. Ten patients with biopsy-proven metastatic cancer were included. Dynamic imaging was started immediately after injection of 300-500 MBq of (99m)Tc-PAMA-cobalamin, and whole-body scintigrams were obtained at 10, 30, 60, 120, and 240 min and after 24 h. The relative tumor activity using SPECT/CT over the tumor region after 4 h was measured in comparison to disease-free lung parenchyma. Patients 3-10 received between 20 and 1,000 μg of cobalamin intravenously before injection of (99m)Tc-PAMA-cobalamin. The study population comprised 4 patients with adenocarcinomas of the lung, 3 with squamous cell carcinomas of the hypopharyngeal region, 1 with prostate adenocarcinoma, 1 with breast, and 1 with colon adenocarcinoma.. The median age of the study group was 61 ± 11 y. Six of 10 patients showed positive tumor uptake on (99m)Tc-PAMA-cobalamin whole-body scintigraphy. The scan was positive in 1 patient with colon adenocarcinoma, in 3 of 4 lung adenocarcinomas, in 1 of 3 hypopharyngeal squamous cell carcinomas, and in 1 breast adenocarcinoma. Renal uptake was between 1% and 3% for the left kidney. Predosing with cobalamin increased the tumor uptake and improved blood-pool clearance. The best image quality was achieved with a predose of 20-100 ug of cold cobalamin. The mean patient dose was 2.7 ± 0.9 mSv/patient.. To our knowledge, we report for the first time on (99m)Tc-PAMA-cobalamin imaging in patients with metastatic cancer disease and show that tumor targeting is feasible.

Topics: Aged; Aged, 80 and over; Biopsy; Female; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms; Organotechnetium Compounds; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Technetium; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Vitamin B 12; Whole Body Imaging

This prospective, observational study investigated the haematological response to darbepoetin alfa (DA) administered every three weeks for the treatment of anaemia. Response was also assessed according to baseline characteristics including iron, folate and vitamin B12 status.. Anaemic adult patients with malignant non-myeloid cancer, starting or having already undergone chemotherapy received DA on day of inclusionand were followed up for up to 24 weeks. Concentration of haemoglobin (Hb), as well as iron, vitamin B12 and folate status where available, were recorded at inclusion, after a treatment period of 9 weeks and up to a maximum of 24 weeks or cessation of DA treatment, whichever was sooner.. The main outcome measure assessed in this study was the percentage of patients reaching a Hb concentration of at least 11 g/dL at least once at any time during the study.. A total of 2912 patients were included. The mean Hb concentration increased from 10.0 g/dL at inclusion to 11.4 g/dL at 9 weeks and 11.8 g/dL at 24 weeks. In 74.6% of patients the target Hb level of 11.0 g/dL or above was reached. After initiation of DA treatment, 9.5% of patients required a blood transfusion by week 9, and 5.6% thereafter. Vitamin B12 and folate status were unknown for 80.3% of patients and the iron status for 73.2% of patients. Compared with patients who remained untreated for vitamin B12 or folate deficiency, a higher percentage of patients with vitamin status within normal limits achieved the target Hb concentration. However, achievement of target Hb level appeared not to be affected by iron status.. In this study, the mean Hb level increased in anaemic cancer patients treated with DA and the majority of patients achieved the target Hb level. In contrast to the recommendations of guidelines (EORTC) encouraging the measurement of iron and vitamin levels, the present study demonstrated that data were not routinely collected for these factors.

Topics: Aged; Anemia; Antineoplastic Agents; Cohort Studies; Darbepoetin alfa; Dietary Supplements; Erythropoietin; Female; Folic Acid; France; Hematinics; Humans; Iron; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prospective Studies; Vitamin B 12

The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC.. Overall, 95 patients received pemetrexed 500 mg/m2 i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B12 supplementation to reduce toxicity. NCI CTC 2.0 was used to rate toxicity. All the adverse events were graded in terms of severity and relation to study treatment. Dose was reduced in case of toxicity and treatment was delayed for up to 42 days from Day 1 of any cycle to allow recovering from study drug-related toxicities. Tumor response was measured using the RECIST criteria.. Patients received a median number of 4 cycles and 97.8% of the planned dose. Overall, 75 patients (78.9% of treated) reported at least one adverse event: 34 (35.8%) had grade 3 as worst grade and only 5 (5.2%) had grade 4. Drug-related events occurred in 57.9% of patients. Neutropenia (8.4%) and leukopenia (6.3 %) were the most common grade 3/4 hematological toxicities. Grade 3 anemia and thrombocytopenia were reported in 3.2% and 2.1% of patients, respectively. Diarrhea (6.3%), fatigue (3.2%) and dyspnea (3.2%) were the most common grade 3/4 non-hematological toxicities. The most common drug-related toxicities (any grade) were pyrexia (11.6%), vomiting, nausea, diarrhea and asthenia (9.5%) and fatigue (8.4%). Tumor Response Rate (CR/PR) in treated patients was 9.2%. The survival at 4.5 months (median follow-up) was 79% and the median PFS was 3.1 months. Twenty patients (21.1%) died mainly because of disease progression.. Patients with locally advanced or metastatic NSCLC could benefit from second-line pemetrexed, with a low incidence of hematological and non-hematological toxicities.

Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dexamethasone; Female; Folic Acid; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Vitamin B 12

In order to identify the biochemical defect(s) responsible for the reduced levels of DNA 5-methylcytosine (5-mCyt) found within highly metastatic (in athymic "nude" mice) variants of the poorly metastatic human melanoma cell line MeWo, the ability of these cells to grow in culture medium devoid of exogenous methionine but containing either homocysteine (Hcy) or 5'-deoxy-5'-methylthioadenosine (MeSAdo) was determined. In contrast to the parental MeWo tumor line, many (but not all) of these malignant variants were completely unable to proliferate in methionine-free homocysteine-containing medium. Many of these malignant variants also exhibited a reduced ability to proliferate in methionine-free MeSAdo-containing medium. Cell lines established from "artificial" metastases of MeWo or its cloned sublines, exhibited no consistent reduction in their ability to grow in methionine-free medium containing either Hcy or MeSAdo. These observations suggest that alterations in S-adenosylmethionine(AdoMet)-dependent transmethylation reactions may contribute to "progression" of the MeWo tumor from a relatively benign to a highly autonomous and malignant state.

Topics: Cell Division; Culture Media; Homocysteine; Humans; Melanoma; Methionine; Neoplasm Metastasis; S-Adenosylmethionine; Tumor Cells, Cultured; Vitamin B 12

The increasing number of publications about the incidence of cancer in small intestine with Crohn's disease shows Ileitis terminalis as an affection promoting cancer. Main problems are early diagnosis and differential diagnosis concerning intestinal stenosis caused by Crohn's recidivation or blind loop after resection. Regular scrutiny of patients with Crohn's disease is of special significance; because of the few present case reports early resection as prophylaxis is not justified.

Topics: Adenocarcinoma; Adult; Crohn Disease; Female; Humans; Ileal Neoplasms; Ileostomy; Intestinal Fistula; Malabsorption Syndromes; Middle Aged; Neoplasm Metastasis; Vitamin B 12

The success of chemotherapy of inoperable endothoracic cancer largely depends on interdisciplinary cooperation. 30 years of research have succeeded in developing some promising combinations of cytostatic agents. Administered sequentially they are better tolerated and this has made outpatient treatment possible. 87 persons had polycytostatic therapy according to the Karrer/Sighart formula. It was followed by a difinite improvement in the general condition of the patients, but without any substantial lengthening of the average survival time. The ACO scheme (Seeber/Schmidt) has been used since April 1977 in 42 persons. Preliminary results indicate a definite prologation of survival time, especially in cases of small-cell bronchogenic carcinoma.

Topics: Adult; Aged; Bronchial Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Pyridoxine; Thoracic Neoplasms; Vinca Alkaloids; Vitamin B 12

36% of a total of chronic liver patients suffered from anaemia and 50.5% of patients affected with liver cirrhosis. In most cases the anaemias were normochrome and hypochrome or hyperchrome only in some cases. In analyzing possible single factors the reductions of vitamin B12 absorption could be made probable by means of the Schilling test and sometimes a folic acid deficiency in macrocyte anaemia with normal vitamin B12 absorption by determining the folic acid content in the serum and by successes of test treatment 82% of patients with liver cirrhosis showed a latent or manifest haemolysis. However, it was only in 1/3 of the patients with liver cirrhosis that the spleen turned out to be the place of an increased degradation of erythrocytes. In some cases an increased erythrocytoclasia into the liver could be identified. Predominantly, however, an increased degradation of erythrocytes in the total RHS had to be assumed. Twice an ineffective erythropoiesis could be found by ferrokinetic examinations. As a whole ferrokinetic examinations cannot be interpreted easily, because their static and dynamic values of iron transport in the plasma volume of liver patients will undergo considerable changes. Patients with disturbances of haematopoiesis and with haemolysis remaining in the latent stage may develop a manifest anaemia because of the influence of additional factors, such as increase of the plasma volume at lowered haematocrit value or microbleedings. The cause of anaemia cannot be concluded with sufficient probability from the type of anaemia; in a single case all pathogenetic factors will rather have to be analyzed. Therapeutic possibilities for hepatogenous anaemia of complex genesis are discussed.

Topics: Adult; Anemia; Chronic Disease; Erythrocyte Count; Erythrocyte Volume; Folic Acid; Hematocrit; Humans; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Neoplasm Metastasis; Vitamin B 12

A patient with metastatic carcinoma of the breast and increased plasma cobalamin binding capacity (about 50 nmol/1) is described. The binding protein was identified as transcobalamin I (TCI) by DEAE cellulose ion-exchange chromatography, Sephadex G200 gel filtration and agar gel electrophoresis. Although the total plasma cobalamin concentration (about 20 nmol/1) was elevated, the patient complained of neurological symptoms in accordance with a functional vitamin B12 deficiency. Hence, an inactivation of the coenzyme is suggested by the demonstration of considerable amounts of 5'-deoxyadenosylcobalamin bound to the plasma TCI. Both urinary excretion of FIGLU and methylmalonic acid were within the reference ranges. Reported cases of increased cobalamin binding in patients with nonhaematological malignancy are reviewed. Further investigations to characterize the function of the cobalamin dependent metabolic pathways are necessary to determine the importance of the increased transcobalamin binding in these patients.

Topics: Blood Proteins; Breast Neoplasms; Chromatography, Gel; Chromatography, Ion Exchange; Electrophoresis, Agar Gel; Female; Formiminoglutamic Acid; Humans; Methylmalonic Acid; Middle Aged; Neoplasm Metastasis; Protein Binding; Transcobalamins; Vitamin B 12; Vitamin B 12 Deficiency

Topics: Blood Proteins; Carcinoma, Bronchogenic; Chromatography, Gel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Binding; Saliva; Transcobalamins; Vitamin B 12

One hundred and thirty-nine patients with non-hematologic malignancy were studied to define the incidence of vitamin B12-related abnormalities and correlate them with clinical findings. Based on vitamin B12-binding patterns, the following relatively distinct groups were defined: (A) 50% had normal results; (B) 6% had very high transcobalamin (TC) I and vitamin B12 levels as reported in isolated instances previously: most had hepatic metastases and early death, and all had definite metastatic disease; (C) 11% had high vitamin B12 levels with little or no unsaturated TC I elevation: most also had hepatic and other metastases and early death; (D) 23% had high vitamin B12-binding capacity with normal TC I and vitamin B12 levels: there were no distinguishing features for this group other than an increased proportion of black patients; and (E) 10% had low vitamin B12 levels, in many cases not associated with vitamin B12 deficiency or other known causes of low serum levels. Thus, high serum vitamin B12 level, with or without unsaturated TC I elevation, usually implies a poor prognosis in a patient with cancer. However, while most such patients have hepatic and other metastases, hepatic involvement was not universal nor did most patients with hepatic disease have high vitamin B12 levels. High serum TC I thus is not always due to increased granulocytic proliferation or to hepatic tumor, and alternative mechanisms for TC I accumulation should be sought.

Topics: Black People; Blood Proteins; Carrier Proteins; Female; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Prognosis; Transcobalamins; Vitamin B 12

Elevation of transcobalamin I and serum vitamin B12 levels has usually been associated with increased granulocytic proliferation, such as occurs in chronic myelogenous leukemia. Two patients with metastatic cancer had extremely high serum vitamin B12 and transcobalamin I levels--greater than those seen in even the most intense granulocytic proliferation--that were not explainable by leukocytosis. The subjects' serum vitamin B12 levels were 18,750 and 21,221 pg per milliliter (normal, 471 plus or minus 174 pg per milliliter, mean plus or minus S.D.) and unsaturated vitamin B12 binding capacity 158,750 and 5,400 pg per milliliter (normal, 1153 plus or minus 313 pg per milliliter) respectively. The abnormally elevated serum binder was shown to be identical with transcobalamin balamin I in every respect. Levels of transcobalamin II and serum third binder were normal. The cause of the binder abnormality is unknown, but factors other than granulocyte proliferation may control or contribute to the production or accumulation of transcobalamin I.

Topics: Adenocarcinoma; Aged; Animals; Blood Proteins; Carcinoma; Carrier Proteins; Cell Division; Chromatography, DEAE-Cellulose; Chromatography, Gel; Cobalt Radioisotopes; Colonic Neoplasms; Female; Granulocytes; Humans; Immune Sera; Leukemia, Myeloid; Leukocyte Count; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Binding; Rabbits; Radioligand Assay; Saliva; Stomach Neoplasms; Vitamin B 12

The absorption of vitamin B12 was assessed using the 58Co-absorption test (Schilling test) in 39 patients in whom ileal loops had been used as urinary diversion after excision of the bladder for transitional cell carcinoma. 29% of the patients were found to absorb less than 12% of the offered dose of labelled vitamin B12 after excluding gastric-mediated malabsorption by the modified Schilling test. Examination of haemoglobin, MCV or vitamin B12 in the peripheral blood gave unreliable indications of the absorptive ability of these patients.

Topics: Adult; Aged; Blood Urea Nitrogen; Female; Hematocrit; Hemoglobinometry; Humans; Ileum; Intestinal Absorption; Male; Middle Aged; Neoplasm Metastasis; Schilling Test; Urinary Bladder Neoplasms; Urinary Diversion; Vitamin B 12

Topics: Blood-Brain Barrier; Brain Neoplasms; Catheterization; Cerebral Hemorrhage; Cobalt Radioisotopes; Epilepsy, Absence; Female; Humans; Injections, Intravenous; Isotope Labeling; Kinetics; Methods; Neoplasm Metastasis; Radiochemistry; Time Factors; Vitamin B 12

Topics: Anemia; Biopsy, Needle; Castration; Cholesterol; Diethylstilbestrol; Estrogens; Folic Acid; Hematuria; Humans; Iron; Lipoproteins; Lymph Nodes; Male; Neoplasm Metastasis; Prostatectomy; Prostatic Neoplasms; Prostatitis; Testosterone; Triglycerides; Uremia; Urination Disorders; Vitamin B 12

Topics: Adult; Aged; Alpha-Globulins; Beta-Globulins; Blood Proteins; Child, Preschool; Chronic Disease; Female; Fever of Unknown Origin; Hodgkin Disease; Humans; Infections; Leukocyte Count; Leukocytosis; Liver Neoplasms; Lymphoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Binding; Splenectomy; Vitamin B 12

Topics: Aged; Alkaline Phosphatase; Bone Neoplasms; Eosinophilia; Humans; Male; Muramidase; Neoplasm Metastasis; Pericardium; Pleura; Pleural Effusion; Pleural Neoplasms; Ribs; Vitamin B 12

Topics: Age Factors; Child; Child, Preschool; Humans; Infant; Neoplasm Metastasis; Neoplasm Regression, Spontaneous; Neuroblastoma; Retrospective Studies; Vitamin B 12

Topics: Age Factors; Bone Marrow; Bone Marrow Cells; Child, Preschool; Cobalt Isotopes; Cyclophosphamide; Female; Ganglia, Autonomic; Ganglioneuroma; Hemoglobins; Humans; Infant; Male; Neoplasm Metastasis; Neoplasms, Nerve Tissue; Neuroblastoma; Prognosis; Radiography; Scoliosis; Vincristine; Vitamin B 12

Topics: Bone Neoplasms; Female; Humans; Infant; Male; Neoplasm Metastasis; Neuroblastoma; Vitamin B 12

Topics: Adrenal Gland Neoplasms; Humans; Infant, Newborn; Infant, Newborn, Diseases; Liver Neoplasms; Male; Mandelic Acids; Neoplasm Metastasis; Neuroblastoma; Prognosis; Skin Neoplasms; Vitamin B 12

Topics: Aged; Female; Hemangiosarcoma; Humans; Infant; Liver Neoplasms; Male; Neoplasm Metastasis; Neuroblastoma; Skin Neoplasms; Vitamin B 12

Topics: Age Factors; Child, Preschool; Cyclophosphamide; Dactinomycin; Humans; Infant; Mechlorethamine; Neoplasm Metastasis; Neuroblastoma; Nitrogen Mustard Compounds; Prognosis; Vincristine; Vitamin B 12

Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Child, Preschool; Female; Fetus; Humans; Infant; Infant, Newborn; Infant, Premature; Neoplasm Metastasis; Neuroblastoma; Pregnancy; Radiography, Abdominal; Teratoma; Vitamin B 12

Topics: Animals; Lung Neoplasms; Lymphatic Metastasis; Melphalan; Neoplasm Metastasis; Neoplasm Transplantation; Rats; Sarcoma, Experimental; Tail; Thiotepa; Vitamin B 12

Topics: Child; Data Collection; Humans; Infant; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Prognosis; United States; Vitamin B 12

Topics: Child; Cyclophosphamide; Dactinomycin; Humans; Infant; Mechlorethamine; Methotrexate; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Retroperitoneal Neoplasms; Toxicology; Urography; Vitamin B 12

Topics: Abdominal Neoplasms; Catecholamines; Child; Cyclophosphamide; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Pelvic Neoplasms; Radiography; Thoracic Neoplasms; Urine; Vitamin B 12

Topics: Antineoplastic Agents; Cobalt Isotopes; Humans; Hydroxocobalamin; Neoplasm Metastasis; Neoplasms; Postoperative Complications; Surgical Procedures, Operative; Vitamin B 12

Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; Liver Neoplasms; Methotrexate; Neoplasm Metastasis; Neoplasms; Prednisone; Testosterone; Thiotepa; Toxicology; Vitamin B 12

Topics: Adolescent; Antineoplastic Agents; Child; Drug Therapy; Humans; Infant; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Sympathetic Nervous System; Vitamin B 12

Topics: Animals; Benzimidazoles; Carcinoma 256, Walker; Neoplasm Metastasis; Neoplasms; Pharmacology; Rats; Research; Sarcoma; Sarcoma, Experimental; Vitamin B 12